Novel approaches and future directions in castration-resistant prostate cancer

被引：16
作者：
Nabhan, C. [1 ]
Parsons, B. [1 ]
Touloukian, E. Z. [2 ]
Stadler, W. M. [3 ]
机构：
[1] Lutheran Gen Hosp, Div Hematol & Oncol, Dept Med, Park Ridge, IL 60068 USA
[2] Providence Hosp, Dept Med, Southfield, MI 48037 USA
[3] Univ Chicago, Dept Med, Chicago, IL 60637 USA
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷 / 09期
关键词：
angiogenesis; castration resistant; immunotherapy; immunomodulatory agents; prostate cancer; receptor antagonists; PHASE-II TRIAL; ENDOTHELIAL GROWTH-FACTOR; MITOXANTRONE PLUS PREDNISONE; RANDOMIZED CONTROLLED-TRIAL; SIPULEUCEL-T APC8015; ABIRATERONE ACETATE; MONOCLONAL-ANTIBODY; IMATINIB MESYLATE; CLINICAL-TRIALS; FACTOR RECEPTOR;
D O I：
10.1093/annonc/mdq639
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent advances in the treatment of castration-resistant prostate cancer (CRPC) have started to change the therapeutic landscape allowing clinicians to choose from a broad range of treatment options. Understanding the mechanisms that transform prostate cancer (PCA) into a castration-resistant state has enabled investigators to explore critical pathways involved in such process allowing for rational therapeutic design. These novel therapies complement the modest success that chemotherapy has demonstrated in recent years. In this review, we discuss the different mechanisms that render PCA castration resistant and elaborate on the nonchemotherapy approaches evolving in CRPC. These include agents targeting the epidermal growth factor receptor, endothelin receptor antagonists, angiogenesis inhibitors, immunomodulatory agents, immunotherapy, novel antiandrogens, and delivery of cytotoxic agents via therapeutic antibodies. This timely review coincides with the identification of newer therapies in this setting affirming our steady movement towards better disease control.
引用
收藏
页码：1948 / 1957
页数：10
相关论文
共 127 条
[61]   A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer [J].
Lin, Amy M. ;
Rini, Brian I. ;
Derynck, Mika K. ;
Weinberg, Vivian ;
Park, Margaret ;
Ryan, Charles J. ;
Rosenberg, Jonathan E. ;
Bubley, Glenn ;
Small, Eric J. .
CLINICAL GENITOURINARY CANCER, 2007, 5 (05) :323-328
[62]   A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy [J].
Lin, Amy M. ;
Rini, Brian I. ;
Weinberg, Vivian ;
Fong, Kristen ;
Ryan, Charles J. ;
Rosenberg, Jonathan E. ;
Fong, Lawrence ;
Small, Eric J. .
BJU INTERNATIONAL, 2006, 98 (04) :763-769
[63]   Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors [J].
Lockhart, A. Craig ;
Rothenberg, Mace L. ;
Dupont, Jakob ;
Cooper, Wendy ;
Chevalier, Paul ;
Sternas, Lars ;
Buzenet, Giliane ;
Koehler, Elizabeth ;
Sosman, Jeffrey A. ;
Schwartz, Lawrence H. ;
Gultekin, David H. ;
Koutcher, Jason A. ;
Donnelly, Edwin F. ;
Andal, Ric ;
Dancy, Isabelle ;
Spriggs, David R. ;
Tew, William P. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) :207-214
[64]   New Therapies for Castration-Resistant Prostate Cancer. [J].
Longo, Dan L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :479-481
[65]   The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions [J].
Lu, Ling ;
Payvandi, Faribourz ;
Wu, Lei ;
Zhang, Ling-Hua ;
Hariri, Robert J. ;
Man, Hon-Wah ;
Chen, Roger S. ;
Muller, George W. ;
Hughes, Christopher C. W. ;
Stirling, David I. ;
Schafer, Peter H. ;
Bartlett, J. Blake .
MICROVASCULAR RESEARCH, 2009, 77 (02) :78-86
[66]   Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer [J].
Madan, Ravi A. ;
Arlen, Philip M. ;
Mohebtash, Mahsa ;
Hodge, James W. ;
Gulley, James L. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (07) :1001-1011
[67]  
Maroni Paul D, 2006, N C Med J, V67, P136
[68]   Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer [J].
Mathew, P ;
Thall, PF ;
Jones, D ;
Perez, C ;
Bucana, C ;
Troncoso, P ;
Kim, SJ ;
Fidler, IJ ;
Logothetis, C .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3323-3329
[69]   A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy [J].
Mathew, P. ;
Tannir, N. ;
Tu, S. M. ;
Carter, C. M. ;
Bekele, N. B. ;
Pagliaro, L. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) :811-815
[70]   Phase II study of sunitinib in men with advanced prostate cancer [J].
Michaelson, M. Dror ;
Regan, M. M. ;
Oh, W. K. ;
Kaufman, D. S. ;
Olivier, K. ;
Michaelson, S. Z. ;
Spicer, B. ;
Gurski, C. ;
Kantoff, P. W. ;
Smith, M. R. .
ANNALS OF ONCOLOGY, 2009, 20 (05) :913-920
234567891011